
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc (STZ-N) faces a mixed outlook according to recent expert reviews. One analyst expresses optimism towards the new CEO and anticipates a positive shift in beer and cocktail sales. Conversely, the other review highlights challenges for the company, noting that its stock and other alcohol-related stocks are currently out of favor. The CEO has mentioned that sales are being adversely affected by ICE raids in popular shopping areas. With Constellation's stock down 36% year-to-date and trading at a low 12x price-to-earnings ratio, the low valuation may be justified by declining sales trends and competition from GLP-1 drugs that impact consumer choices. The contrasting viewpoints indicate a cautious sentiment surrounding the future performance of the company.
(A Top Pick Feb 24/16. Up 25%.) Switched out of this given that it was a consumer staples name, and into more of the cyclical areas. He still likes the name. Trading at 21X forward earnings with a 17% long-term growth rate. Sales going forward could be challenged by Pres. Trump’s potential policy to raise tariffs on Mexican imports.
This has a number of things in its favour right now. Technically it is in a distinct upward trend, outperforming the market with positive momentum, so the technicals are good. Seasonality is more important, because on a seasonal basis it historically reaches a very important low right around the middle of October, and moves higher right through until the middle of February.
This has had tremendous price momentum. It is really a consolidator of wineries and alcoholic beverages. Valuation is OK. Good ROE’s, a little expensive on EB to EBITDA and Price to Free Cash Flow. They have a decent balance sheet, so can continue their strategy of rolling up smaller competitors. Dividend yield of 1%. Not super cheap.